Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs
Pituitary adenomas are neuroendocrine tumors that produce different endocrine and metabolic alterations, including hyperprolactinemia, acromegaly and Cushing's disease. These different clinical features of pituitary tumors are the result of the overproduction of hormones produced by the differe...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_15680088_v5_n3_p259_PaezPereda |
| Aporte de: |
| id |
todo:paper_15680088_v5_n3_p259_PaezPereda |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_15680088_v5_n3_p259_PaezPereda2023-10-03T16:26:43Z Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs Paez-Pereda, M. Giacomini, D. Echenique, C. Stalla, G.K. Holsboer, F. Arzt, E. 1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 1,4 diamino 1,4 bis(2 aminophenylthio) 2,3 dicyanobutadiene 2 (2 amino 3 methoxyphenyl)chromone angiopeptin bone morphogenetic protein cell nucleus receptor corticotropin cyclic AMP dependent protein kinase cytokine estradiol estrogen derivative estrogen receptor glycoprotein gp 130 growth hormone hypophysis hormone mitogen activated protein kinase n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide nuclear receptor related factor 1 octreotide peroxisome proliferator activated receptor gamma prolactin protein kinase (calcium,calmodulin) protein kinase C retinoic acid receptor retinol rosiglitazone Smad protein transforming growth factor beta unindexed drug acromegaly cancer inhibition cell proliferation cell type clinical feature Cushing syndrome drug targeting endocrine disease enzyme activation enzyme inhibition hormonal regulation hormone inhibition hormone synthesis human hyperprolactinemia hypophysis adenoma hypophysis cell metabolic disorder neuroendocrine tumor nonhuman prolactin synthesis prolactinoma protein family protein protein interaction review secretory cell signal transduction transcription regulation Adrenocorticotropic Hormone Animals Cytokines Drug Delivery Systems Gene Expression Regulation Humans Neurosecretory Systems Pituitary Neoplasms Prolactin Receptors, Cytokine Signal Transduction Transforming Growth Factor beta Pituitary adenomas are neuroendocrine tumors that produce different endocrine and metabolic alterations, including hyperprolactinemia, acromegaly and Cushing's disease. These different clinical features of pituitary tumors are the result of the overproduction of hormones produced by the different pituitary cell types. Recent advances in the understanding of the signaling pathways that control hormone production in pituitary cells provide a source of potential therapeutic targets. In ACTH-secreting cells, the mechanisms that control hormone biosynthesis have been clarified to a great extent, indicating a number of protein kinases and ligand-activated nuclear receptors as targets for experimental drugs. ACTH production requires the activation of signal transduction through the PKA, the MAPK and the CamK pathways. These pathways activate nuclear receptors, including Nur and PPAR gamma. The inhibition of these kinases and nuclear receptors has been shown to produce therapeutic effects in mouse models of Cushing's syndrome. On the other hand, the signaling pathways that control prolactin and growth hormone production also have potential targets. It has been recently shown that SMAD proteins activated by growth factors of the TGF beta and BMP family interact with estrogen receptors to stimulate the proliferation of prolactin and growth hormone-secreting cells. Cytokines that bind to the membrane protein gp130 also stimulate the proliferation of these cells. The inhibition of both of these pathways results in the decrease of tumor growth in animal models of prolactinoma. Therefore, the study of signaling pathways that control hormone production and proliferation is a good source of candidate targets in pituitary tumors. © 2005 Bentham Science Publishers Ltd. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_15680088_v5_n3_p259_PaezPereda |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 1,4 diamino 1,4 bis(2 aminophenylthio) 2,3 dicyanobutadiene 2 (2 amino 3 methoxyphenyl)chromone angiopeptin bone morphogenetic protein cell nucleus receptor corticotropin cyclic AMP dependent protein kinase cytokine estradiol estrogen derivative estrogen receptor glycoprotein gp 130 growth hormone hypophysis hormone mitogen activated protein kinase n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide nuclear receptor related factor 1 octreotide peroxisome proliferator activated receptor gamma prolactin protein kinase (calcium,calmodulin) protein kinase C retinoic acid receptor retinol rosiglitazone Smad protein transforming growth factor beta unindexed drug acromegaly cancer inhibition cell proliferation cell type clinical feature Cushing syndrome drug targeting endocrine disease enzyme activation enzyme inhibition hormonal regulation hormone inhibition hormone synthesis human hyperprolactinemia hypophysis adenoma hypophysis cell metabolic disorder neuroendocrine tumor nonhuman prolactin synthesis prolactinoma protein family protein protein interaction review secretory cell signal transduction transcription regulation Adrenocorticotropic Hormone Animals Cytokines Drug Delivery Systems Gene Expression Regulation Humans Neurosecretory Systems Pituitary Neoplasms Prolactin Receptors, Cytokine Signal Transduction Transforming Growth Factor beta |
| spellingShingle |
1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 1,4 diamino 1,4 bis(2 aminophenylthio) 2,3 dicyanobutadiene 2 (2 amino 3 methoxyphenyl)chromone angiopeptin bone morphogenetic protein cell nucleus receptor corticotropin cyclic AMP dependent protein kinase cytokine estradiol estrogen derivative estrogen receptor glycoprotein gp 130 growth hormone hypophysis hormone mitogen activated protein kinase n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide nuclear receptor related factor 1 octreotide peroxisome proliferator activated receptor gamma prolactin protein kinase (calcium,calmodulin) protein kinase C retinoic acid receptor retinol rosiglitazone Smad protein transforming growth factor beta unindexed drug acromegaly cancer inhibition cell proliferation cell type clinical feature Cushing syndrome drug targeting endocrine disease enzyme activation enzyme inhibition hormonal regulation hormone inhibition hormone synthesis human hyperprolactinemia hypophysis adenoma hypophysis cell metabolic disorder neuroendocrine tumor nonhuman prolactin synthesis prolactinoma protein family protein protein interaction review secretory cell signal transduction transcription regulation Adrenocorticotropic Hormone Animals Cytokines Drug Delivery Systems Gene Expression Regulation Humans Neurosecretory Systems Pituitary Neoplasms Prolactin Receptors, Cytokine Signal Transduction Transforming Growth Factor beta Paez-Pereda, M. Giacomini, D. Echenique, C. Stalla, G.K. Holsboer, F. Arzt, E. Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| topic_facet |
1 [n,o bis(5 isoquinolinesulfonyl) n methyltyrosyl] 4 phenylpiperazine 1,4 diamino 1,4 bis(2 aminophenylthio) 2,3 dicyanobutadiene 2 (2 amino 3 methoxyphenyl)chromone angiopeptin bone morphogenetic protein cell nucleus receptor corticotropin cyclic AMP dependent protein kinase cytokine estradiol estrogen derivative estrogen receptor glycoprotein gp 130 growth hormone hypophysis hormone mitogen activated protein kinase n (2 phenylcyclopentyl)azacyclotridecan 2 imine n [2 (4 bromocinnamylamino)ethyl] 5 isoquinolinesulfonamide nuclear receptor related factor 1 octreotide peroxisome proliferator activated receptor gamma prolactin protein kinase (calcium,calmodulin) protein kinase C retinoic acid receptor retinol rosiglitazone Smad protein transforming growth factor beta unindexed drug acromegaly cancer inhibition cell proliferation cell type clinical feature Cushing syndrome drug targeting endocrine disease enzyme activation enzyme inhibition hormonal regulation hormone inhibition hormone synthesis human hyperprolactinemia hypophysis adenoma hypophysis cell metabolic disorder neuroendocrine tumor nonhuman prolactin synthesis prolactinoma protein family protein protein interaction review secretory cell signal transduction transcription regulation Adrenocorticotropic Hormone Animals Cytokines Drug Delivery Systems Gene Expression Regulation Humans Neurosecretory Systems Pituitary Neoplasms Prolactin Receptors, Cytokine Signal Transduction Transforming Growth Factor beta |
| description |
Pituitary adenomas are neuroendocrine tumors that produce different endocrine and metabolic alterations, including hyperprolactinemia, acromegaly and Cushing's disease. These different clinical features of pituitary tumors are the result of the overproduction of hormones produced by the different pituitary cell types. Recent advances in the understanding of the signaling pathways that control hormone production in pituitary cells provide a source of potential therapeutic targets. In ACTH-secreting cells, the mechanisms that control hormone biosynthesis have been clarified to a great extent, indicating a number of protein kinases and ligand-activated nuclear receptors as targets for experimental drugs. ACTH production requires the activation of signal transduction through the PKA, the MAPK and the CamK pathways. These pathways activate nuclear receptors, including Nur and PPAR gamma. The inhibition of these kinases and nuclear receptors has been shown to produce therapeutic effects in mouse models of Cushing's syndrome. On the other hand, the signaling pathways that control prolactin and growth hormone production also have potential targets. It has been recently shown that SMAD proteins activated by growth factors of the TGF beta and BMP family interact with estrogen receptors to stimulate the proliferation of prolactin and growth hormone-secreting cells. Cytokines that bind to the membrane protein gp130 also stimulate the proliferation of these cells. The inhibition of both of these pathways results in the decrease of tumor growth in animal models of prolactinoma. Therefore, the study of signaling pathways that control hormone production and proliferation is a good source of candidate targets in pituitary tumors. © 2005 Bentham Science Publishers Ltd. |
| format |
JOUR |
| author |
Paez-Pereda, M. Giacomini, D. Echenique, C. Stalla, G.K. Holsboer, F. Arzt, E. |
| author_facet |
Paez-Pereda, M. Giacomini, D. Echenique, C. Stalla, G.K. Holsboer, F. Arzt, E. |
| author_sort |
Paez-Pereda, M. |
| title |
Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| title_short |
Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| title_full |
Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| title_fullStr |
Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| title_full_unstemmed |
Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| title_sort |
signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs |
| url |
http://hdl.handle.net/20.500.12110/paper_15680088_v5_n3_p259_PaezPereda |
| work_keys_str_mv |
AT paezperedam signalingprocessesintumoralneuroendocrinepituitarycellsaspotentialtargetsfortherapeuticdrugs AT giacominid signalingprocessesintumoralneuroendocrinepituitarycellsaspotentialtargetsfortherapeuticdrugs AT echeniquec signalingprocessesintumoralneuroendocrinepituitarycellsaspotentialtargetsfortherapeuticdrugs AT stallagk signalingprocessesintumoralneuroendocrinepituitarycellsaspotentialtargetsfortherapeuticdrugs AT holsboerf signalingprocessesintumoralneuroendocrinepituitarycellsaspotentialtargetsfortherapeuticdrugs AT arzte signalingprocessesintumoralneuroendocrinepituitarycellsaspotentialtargetsfortherapeuticdrugs |
| _version_ |
1807321624687411200 |